Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer

NCT00573989 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

27

Enrollment

OTHER

Sponsor class

Stopped Drug Supply Issue

Conditions

Head and Neck Cancer

Interventions

DRUG: erlotinib hydrochloride
DRUG: pemetrexed disodium
PROCEDURE: quality-of-life assessment
RADIATION: intensity-modulated radiation therapy

Sponsor

Wake Forest University Health Sciences

Collaborators

[object Object]